Cart
sales@molnova.com
Imidazole
CAS No. 288-32-4
Imidazole ( Glyoxaline;13-Diaza-24-cyclopentadiene;13-diazole )
Catalog No. M20052 CAS No. 288-32-4
Imidazole is a planar 5-membered ring and a highly polar compound. It has been used extensively as a corrosion inhibitor. Imidazole is incorporated into many important biological molecules.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameImidazole
-
NoteResearch use only not for human use.
-
Brief DescriptionImidazole is a planar 5-membered ring and a highly polar compound. It has been used extensively as a corrosion inhibitor. Imidazole is incorporated into many important biological molecules.
-
DescriptionImidazole is a planar 5-membered ring and a highly polar compound. It has been used extensively as a corrosion inhibitor. Imidazole is incorporated into many important biological molecules.
-
SynonymsGlyoxaline;13-Diaza-24-cyclopentadiene;13-diazole
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number288-32-4
-
Formula Weight68.08
-
Molecular FormulaC3H4N2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mg/mL;Water: 95 mg/mL
-
SMILESc1c[nH]cn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Arispe N. et al.: Biophys. J. 95 4879 (2008) .
molnova catalog
related products
-
MAC-545496
MAC-545496 is a glycopeptide-resistance-associated protein R (GraR) inhibitor, is an antivirulence agent.
-
Geranylacetone
Geranylacetone has trypanostatic activity and could protect animals against the T. congolense-induced anaemia through the inhibition of sialidase and/or the protection of the parasite-induced hepatosplenomegaly.
-
Diosmetin-7-O-beta-D...
Diosmetin-7-O-beta-D-glucopyranoside has antioxidant activity.
